Dr Claude Bertrand
Executive Vice President Research and Development, Chief Scientific Officer at Servier.
With over 25 years’ experience in research and development and international operations within a number of leading pharmaceutical groups (Novartis, Roche, Pfizer, AstraZeneca and Ipsen), Claude Bertrand joined Servier in 2017 as Executive Director R&D and Chief Scientific Officer.
In 2018, he was appointed to the Group’s Executive Committee and the role of Executive Vice President Research and Development.
Claude Bertrand also sits on the boards of directors of Eclosion2 and MAAT Pharma. He is President of the scientific committee of LabEx Medalis and Vice President of MEDICEN.
After graduating as a Doctor of Pharmacy from the University of Strasbourg, he completed a PhD and continued onto postdoctoral studies at the University of California, San Francisco, conducting research in immunopharmacology and neurogenic inflammation.